Friday, April 19, 2024
4/19/2024
Small cell lung cancer (SCLC) is a highly aggressive malignancy that has limited therapeutic options. Treatment of SCLC with immune checkpoint inhibitors has been associated with response rates of 10-14% and increases in survival when combined with chemotherapy. Despite these advances, patients diagnosed with SCLC have a median overall survival of ~1 year, emphasizing the critical need for identifying druggable targets that contribute to SCLC progression. The oncogenic MUC1-C protein appeared in mammals to protect pulmonary and other types of epithelial cells from loss of homeostasis associated with exposure to the external environment. MUC1-C activates inflammatory, proliferative and remodeling signaling pathways that contribute to the wound healing response. Importantly, in settings of chronic inflammation with repetitive cycles of damage and repair, prolonged MUC1-C activation promotes cancer progression. There is no known involvement of MUC1-C in SCLC. Our proposed work addresses the previously unexplored hypothesis that MUC1-C plays a master role in promoting SCLC progression and is a druggable target for SCLC treatment. This hypothesis is based in part on preliminary observations that MUC1-C promotes reprogramming of SCLC cell chromatin architecture, which is necessary for pluripotency and lineage plasticity, and that targeting MUC1-C abrogates those alterations in chromatin accessibility. Our hypothesis is further supported by findings that MUC1-C activates MYC signaling in SCLC cells and induces the expression of NOTCH2, a marker of pulmonary neuroendocrine (NE) stem cells that initiate repair after injury and are the proposed cell of SCLC origin. Along these lines, targeting MUC1-C suppresses MYC and NOTCH2 expression and therefore represents an attractive therapeutic strategy for the inhibition of SCLC cell self-renewal capacity and tumorigenicity. MUC1-C is being targeted with CAR-T cells, antibody-drug conjugates and a direct inhibitor of MUC1-C function that are under clinical development. Our studies to assess the effects of targeting MUC1-C will be performed on human SCLC cell lines growing in vitro and as tumor xenografts and on SCLC PDX tumor models. The studies will be integrated with the impact of targeting MUC1-C on SCLC cell chromatin remodeling and gene expression patterns in association with the suppression of lineage plasticity, stemness and tumorigencity. The overall objective of the proposed work is to advance our understanding of SCLC pathogenesis by demonstrating that MUC1-C represents a previously unrecognized effector which plays an important role in the progression of this highly aggressive malignancy. MUC1-C is a druggable target that, based on our findings, could provide new opportunities for advancing SCLC treatment.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
